Literature DB >> 25418427

Relation of epicardial fat thickness to the severity of heart failure in patients with nonischemic dilated cardiomyopathy.

Mehmet Mustafa Tabakci1, Halil İbrahim Durmuş, Anil Avci, Cuneyt Toprak, Serdar Demir, Uğur Arslantaş, Sinan Cerşit, Serdar Fidan, Şeyhmus Kulahçioğlu, Ulaankhuu Batgerel, Ramazan Kargin.   

Abstract

BACKGROUND: The aim of this study was to assess whether epicardial fat thickness (EFT) is associated with the severity of heart failure in patients with nonischemic dilated cardiomyopathy (NICMP).
METHODS: The study group was composed of 93 patients with NICMP and38 age- and sex-matched healty individuals as the control group. The EFT was identified during end-systole at the point on the free wall of the right ventricle.
RESULTS: Patients with NICMP had significantly lower mean EFT than those in the control group (4.1 ± 0.8 vs. 6.1 ± 1.8 mm, P < 0.001). EFT was thinnest in patients with New York Heart Association (NYHA) functional class III or IV (3.5 ± 0.5, P < 0.001). There was a significant correlation between EFT, left ventricle EF (r = 0.540 P < 0.001), and B-type natriuretic peptide (BNP) (r = -0.695, P < 0.001) values in patients with NICMP. In addition, when EFT was corrected for BMI, EFT/BMI was lower in patients with NYHA functional class III-IV than patients with NYHA class I-II and control group (0.13 ± 0.01, 0.16 ± 0.02, 0.23 ± 0.04, respectively; P < 0.001). There was a significant correlation between EFT/BMI, left ventricle EF (r = 0.489, P < 0.001), and BNP (r = -0.549, P < 0.001) in patients with NICMP. In multivariate regression analysis, EFT (P = 0.009), BNP (P = 0.039), and left atrium volume index (P = 0.039) were independently associated with impaired functional status.
CONCLUSION: Echocardiographic EFT is an inexpensive, simple, and readily available marker that may be used to asses the severity of chronic heart failure in patients with NICMP.
© 2014, Wiley Periodicals, Inc.

Entities:  

Keywords:  dilated cardiomyopathy; echocardiography; ejection fraction; heart failure

Mesh:

Substances:

Year:  2014        PMID: 25418427     DOI: 10.1111/echo.12796

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  5 in total

Review 1.  B-type natriuretic peptide levels and benign adiposity in obese heart failure patients.

Authors:  Vasiliki Katsi; Maria Marketou; Alexios S Antonopoulos; Dimitrios Vrachatis; Fragkiskos Parthenakis; Dimitris Tousoulis
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

2.  Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure.

Authors:  Luis M Pérez-Belmonte; Inmaculada Moreno-Santos; Juan J Gómez-Doblas; José M García-Pinilla; Luis Morcillo-Hidalgo; Lourdes Garrido-Sánchez; Concepción Santiago-Fernández; María G Crespo-Leiro; Fernando Carrasco-Chinchilla; Pedro L Sánchez-Fernández; Eduardo de Teresa-Galván; Manuel Jiménez-Navarro
Journal:  Int J Med Sci       Date:  2017-07-20       Impact factor: 3.738

3.  The relationship between epicardial fat thickness and high-grade varicocele.

Authors:  Isa Sincer; Emrah Erdal; Adnan Gucuk; Emre Bostancı; Yilmaz Gunes
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

Review 4.  A systematic review exploring the significance of measuring epicardial fat thickness in correlation to B-type natriuretic peptide levels as prognostic and diagnostic markers in patients with or at risk of heart failure.

Authors:  Thembeka A Nyawo; Phiwayinkosi V Dludla; Sithandiwe E Mazibuko-Mbeje; Sinenhlanhla X H Mthembu; Tawanda M Nyambuya; Bongani B Nkambule; Hanél Sadie-Van Gijsen; Hans Strijdom; Carmen Pheiffer
Journal:  Heart Fail Rev       Date:  2021-10-20       Impact factor: 4.214

5.  Epicardial Adipose Tissue in Heart Failure Phenotypes - A Meta-Analysis.

Authors:  Eduardo Thadeu de Oliveira Correia; Letícia Mara Dos Santos Barbetta; Orlando Santos da Costa; Pedro El Hadj de Miranda; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2022-03       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.